Hat Trick For Xofluza As Canadian, Swiss & Australian Regulators Join Forces

 
• By Neena Brizmohun

Xofluza is also the first non-cancer drug to be reviewed under the Australia-Canada-Singapore-Switzerland (ACSS) Consortium’s work-sharing initiative.

Three hands fist bump
Three regulatory agencies collaborated on their review of Xofluza • Source: Shutterstock

More from Product Reviews

More from Pink Sheet